O. Ben-Aharon

Willingness to pay for cancer prevention, screening, diagnosis, and treatment: a systematic review

G. Iskrov, D. Greenberg, I. Sagy, 2023, Expert review of pharmacoeconomics & outcomes research.

Evaluation of a universal hepatitis B vaccination program and antenatal screening for hepatitis B surface antigen: Results from a real-world study 2015-2016.

E. Anis, R. Magnezi, Z. Ben‐Ari, 2021, Vaccine.

Mature Versus Registration Studies of Immuno-Oncology Agents: Does Value Improve With Time?

M. Leshno, D. Goldstein, R. Magnezi, 2020, JCO oncology practice.

Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?

M. Leshno, D. Goldstein, R. Magnezi, 2019, The oncologist.

Association of Immunotherapy With Durable Survival as Defined by Value Frameworks for Cancer Care

M. Leshno, D. Goldstein, R. Magnezi, 2017, JAMA oncology.

Does drug price-regulation affect healthcare expenditures?

R. Magnezi, O. Shavit, O. Ben-Aharon, 2016, The European Journal of Health Economics.

Willingness to pay for an mRNA-based anti-cancer treatment: results from a contingent valuation study in Israel

G. Iskrov, O. Ben-Aharon, Ruslan Sergienko, 2024, Israel journal of health policy research.

Improving on Tail-of-the-Curve Evaluation With the American Society of Clinical Oncology Value Framework-Reply.

D. Goldstein, Omer Ben-Aharon, O. Ben-Aharon, 2018, JAMA oncology.